Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Status: RECRUITING

Eligibility Criteria

Age: 40 years to 70 years old

This study is NOT accepting healthy

Healthy Volunteers: volunteers

Key

Inclusion Criteria:

* Male or female aged 40 to 70 years (inclusive) * Diagnosis of RMS according to the 2017 McDonald diagnostic criteria * Treated with ocrelizumab according to routine clinical practice and at standard dose * Neurologically stable within 30 days * Suitable to be switched to remibrutinib based on physician judgement or patient preference Key

---

Exclusion Criteria:

* Diagnosis of primary progressive multiple sclerosis (PPMS) according to the revised 2017 McDonald criteria * History of clinically significant Central Nervous System disease or neurological disorders * History of confirmed Progressive Multifocal Leukoencephalopathy or neurological symptoms consistent * Active clinically significant systemic bacterial, viral, parasitic or fungal infections * Active, chronic disease of the immune system other than MS * Severe cardiac disease or significant findings on the ECG * Participant who is unable to undergo MRI scans * History of life-threatening infusion or injection reaction related to ocrelizumab Other inclusion and exclusion criteria may apply

Conditions & Interventions

Interventions:
DRUG: Remibrutinib oral treatment, DRUG: Ocrelizumab
Conditions:
Relapsing Multiple Sclerosis
Keywords:
MS, RMS, Remibrutinib, LOU064, Ocrelizumab, Age, MRI, T2 lesions, NEDA-3

More Information

Contact(s): Novartis Pharmaceuticals - novartis.email@novartis.com
Principal Investigator:
IRB
Number:
System ID: NCT06846281
